Results 161 to 170 of about 39,457 (305)

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, Volume 20, Issue 6, Page 1643-1660, June 2026.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Deoxycytidine kinase inhibition: Rewiring tumor nucleotide metabolism for therapeutic gain. [PDF]

Nucleosides Nucleotides Nucleic Acids
Clark PM, Thompson CB, Schultz KA.
europepmc   +1 more source

Host-Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus. [PDF]

Microbiologyopen
A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Lorente-Torres B, Ferrero HÁ, Castañera P, Llano-Verdeja J, Fernández-Martínez S, Herrero-González A, Javadimarand F, López R, Aparicio JF, Edwards AM, Behrends V, Mateos LM, Mourenza Á, Letek M.   +13 more
europepmc   +2 more sources

Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration

Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu, Yongjie Tang, Sidi Liu, Tao Xu, Qian Liu   +4 more
wiley   +1 more source

Doxecitine and Doxribtimine: First Approval. [PDF]

Paediatr Drugs
Blair HA.
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Simultaneous quantification of cytidine, methylcytidine, and hydroxymethylcytidine by isotope-dilution LC-MS/MS with application to mouse liver samples. [PDF]

J Chromatogr A
Mishra P, Ma J, Xie H, Li F, Tsai RYL, Liang D.   +5 more
europepmc   +1 more source

Human Deoxycytidine Kinase

Journal of Biological Chemistry, 1989
S H Huang, J M Tomich, H Wu, A Jong, J Holcenberg   +4 more
openaire   +1 more source

Multimodal Multiorgan‐on‐a‐Chip Platform for Probing Liver‐Tumor Interactions and Advancing Prodrug Screening

Advanced Science, Volume 13, Issue 34, 19 June 2026.
This work introduces a multimodal multi‐OoC platform that overcomes current limitations in liver‐tumor interaction studies and prodrug screening. By integrating dynamic microfluidic circuits, electrochemical sensing, and mass analysis, this platform enables non‐invasive, longitudinal monitoring of drug metabolism and hepatotoxicity, offering a ...
Dan Wang, Yisong Huang, Weijian Zhao, Tian Chen, Siyu Bai, Denghui Guo, Mengying Wang, Yaoyao Zhao, Liang Zhao, Guangsheng Guo, Xiayan Wang   +10 more
wiley   +1 more source

Epigenetic drug control of Clec4g/LSECtin expression reduces fibrosis burden in cirrhosis. [PDF]

Hepatol Commun
Ángel-Gomis E, Gómez-Hurtado I, Fernández-Barrena MG, Juanola O, Martínez-López S, Boix P, Ávila MA, Caparrós E, Francés R.   +8 more
europepmc   +1 more source